A specific database for providing local and national level of integration of clinical data in cystic fibrosis T. Leal, G. Reychler, P. Mailleux, J. Gigi,

Slides:

Advertisements

Similar presentations

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Advertisements

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Cost of care and clinical condition in paediatric cystic fibrosis patients Ulrich Baumann, Christiane Stocklossa, Wolfgang Greiner, Johann-Matthias Graf.

Adiponectin and body composition in cystic fibrosis

Achromobacter species in cystic fibrosis: Cross-infection caused by indirect patient-to- patient contact C.R. Hansen, T. Pressler, W. Ridderberg, H.K.

Prevalence and impact on FEV1 decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with Cystic Fibrosis E.

Dorene F. Balmer, Joan I. Schall, Virginia A. Stallings

Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients R. Cantón, N. Cobos,

Infections in Patients with Cystic Fibrosis

Development, validation, and implementation of a questionnaire assessing disease knowledge and understanding in adult cystic fibrosis patients Karen.

Type 3 secretion system effector genotype and secretion phenotype of longitudinally collected Pseudomonas aeruginosa isolates from young children diagnosed.

Epidemic Pseudomonas aeruginosa infection in patients with cystic fibrosis is not a risk factor for poor clinical Outcomes following lung transplantation

Impact of polymorphism of Multidrug Resistance-associated Protein 1 (ABCC1) gene on the severity of cystic fibrosis Andrea Mafficini, Myriam Ortombina,

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

John Widger, Sarath Ranganathan, Philip J. Robinson

The ease of breathing test tracks clinical changes in cystic fibrosis

Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi,

A. Oliver, A. Mena Clinical Microbiology and Infection

Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis Malin Carlsson, Leif Eriksson, Tania Pressler, Ragnhild Kornfält,

Pulmonary exacerbations in CF patients with early lung disease

The applicability of urinary creatinine as a method of specimen normalization in the cystic fibrosis population Brandie D. Wagner, Frank J. Accurso,

Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection Charles R. Esther, Rongpong Plongla, Alan Kerr, Feng-Chang Lin,

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Cynthia M. Ward, Tara Brinkman, Keith J. Slifer, Shruti M. Paranjape

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

The Journal of Cystic Fibrosis: Sunny perspectives

P. aeruginosa in the paranasal sinuses and transplanted lungs have similar adaptive mutations as isolates from chronically infected CF lungs Oana Ciofu,

Charles R. Esther, Denise A

Asians with cystic fibrosis in the UK have worse disease outcomes than clinic matched white homozygous ΔF508 controls Jonathan McCormick, Simon A. Ogston,

UK Cystic Fibrosis Registry Annual Data Report 2017

A.H. Gifford Journal of Cystic Fibrosis

M. C. Alanin, K. G. Nielsen, C. von Buchwald, M. Skov, K. Aanaes, N

Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden Per Kristian Knudsen, Hanne.

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI®

Felix Ratjen, Florian Brockhaus, Gerhild Angyalosi

Higher Interleukin-7 serum concentrations in patients with cystic fibrosis correlate with impaired lung function Julia Seyfarth, Sutharsan Sivagurunathan,

Elliott C. Dasenbrook, Gregory S. Sawicki Journal of Cystic Fibrosis

Chee Y. Ooi, Peter R. Durie Journal of Cystic Fibrosis

D.Y.F. Mak, J. Sykes, A.L. Stephenson, L.C. Lands

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa Karen O. McKay, Peter J. Cooper, Peter P. van.

Michael D. Parkins, R. Andres Floto Journal of Cystic Fibrosis

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal

Lung clearance index during hospital admission in school-age children with cystic fibrosis Liam Welsh, Christopher Nesci, Haily Tran, Marisol Tomai,

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

Determining presence of lung disease in young children with cystic fibrosis: Lung clearance index, oxygen saturation and cough frequency E.M. Bakker,

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

The effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal study Dr David C.

Table of contents The Journal for Nurse Practitioners

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

Patient segregation and aggressive antibiotic eradication therapy can control methicillin- resistant Staphylococcus aureus at large cystic fibrosis centres

Beta-lactam allergy in adults with cystic fibrosis

Daniel V Schidlow, M.D. Journal of Cystic Fibrosis

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

B. Martha, D. Croisier, A. Fanton, K. Astruc, L. Piroth, F. Huet, P

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis D.J. Touw, A.J. Knox,

Cystic fibrosis and pregnancy in the modern era: A case control study

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

A specific database for providing local and national level of integration of clinical data in cystic fibrosis T. Leal, G. Reychler, P. Mailleux, J. Gigi, V. Godding, P. Lebecque Journal of Cystic Fibrosis Volume 6, Issue 3, Pages 187-193 (May 2007) DOI: 10.1016/j.jcf.2006.07.002 Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 1 Data management diagram used in the CFdbase software. Journal of Cystic Fibrosis 2007 6, 187-193DOI: (10.1016/j.jcf.2006.07.002) Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 2 Datasheet for input, update, search and retrieval functions from an actual CF patient registered with the CFdbase software. 1 — Patient identification; 2 — Toolbars allowing to access multiple clinical, investigational and administrative patient data modules; 3 — Toolbar allowing to select separate modules to be used by the paramedical staff (physiotherapist, nurse, social worker, nutritionist, psychologist, varia); 4 — Toolbar allowing to access a single screen displaying summarized information of the patient including basic medical and historical data, phenotype–genotype, longitudinal graphical representation of weight, BMI (body mass index), lung function and bacteriology data drawn as a 5-year span table; 5 — Multiple thumbnail presentations to access modules for collection data, as indicated; 6 — Area allocated for alarm icons, such as that indicating the presence of chronic colonization by Pseudomonas aeruginosa; 7 — Formatted data-field definitions for easy checking-off; 8 — Blank field for additional free-text annotation. Journal of Cystic Fibrosis 2007 6, 187-193DOI: (10.1016/j.jcf.2006.07.002) Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 3 One-screen summary of clinical and laboratory data of an actual CF patient registered with the CFdbase software. BMI is expressed in Z score according to age. FEV1 is expressed as percentage of predicted values for age and sex according to Knudson et al [6]. Weight is expressed as percentage of ideal weight. Results from cultures performed in every outpatient visit are drawn as a 5-year span table in which each successive month is defined. Journal of Cystic Fibrosis 2007 6, 187-193DOI: (10.1016/j.jcf.2006.07.002) Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 4 Collective spirometric data of 118 CF patients attending our centre at the end of 2005. Data are processed for the whole, paediatric and adult population, also assigned according to the degree of severity of the lung disease [11]. Journal of Cystic Fibrosis 2007 6, 187-193DOI: (10.1016/j.jcf.2006.07.002) Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 5 Collective microbiological data of 141 CF patients attending our centre at the end of 2005. Y-axis indicates the number of infected patients for the listed pathogens. Corresponding percentages are indicated in the top of columns. Journal of Cystic Fibrosis 2007 6, 187-193DOI: (10.1016/j.jcf.2006.07.002) Copyright © 2006 Elsevier B.V. Terms and Conditions